Intranasal Insulin for COVID-19-related Smell Loss : Intranasal Insulin for COVID-19-related Smell Loss
The aim of this study was to quantify the improvement in olfaction of 27 post-COVID-19 patients, after three intreventions of intranasal insulin during a four week period, with the help of the Threshold, Discrimination and Identification (TDI) score evaluated with Sniffin Sticks®..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ClinicalTrials.gov - (2022) vom: 18. Juli Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: July 18, 2022, Last downloaded: ClinicalTrials.gov processed this data on July 25, 2022, Last updated: July 27, 2022 |
|---|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG008581681 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG008581681 | ||
| 003 | DE-627 | ||
| 005 | 20230425191732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220720s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG008581681 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT05461365 | ||
| 035 | |a (UBBS_Klinische_Studien)01007 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Intranasal Insulin for COVID-19-related Smell Loss |b Intranasal Insulin for COVID-19-related Smell Loss |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: July 18, 2022, Last downloaded: ClinicalTrials.gov processed this data on July 25, 2022, Last updated: July 27, 2022 | ||
| 520 | |a The aim of this study was to quantify the improvement in olfaction of 27 post-COVID-19 patients, after three intreventions of intranasal insulin during a four week period, with the help of the Threshold, Discrimination and Identification (TDI) score evaluated with Sniffin Sticks®. | ||
| 650 | 2 | |a COVID-19 | |
| 650 | 2 | |a Anosmia | |
| 650 | 2 | |a Olfaction Disorders | |
| 650 | 4 | |a Medical Condition: Anosmia, Smell Loss, Paraosmia, Hyposmia, COVID-19 | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 3 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2022) vom: 18. Juli |
| 773 | 1 | 8 | |g year:2022 |g day:18 |g month:07 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05461365 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 18 |c 07 | ||